Objectives: To determine the potency and reproducibility of milbemycin oxime when compounded as an aqueous suspension (20 mg/mL). clinical significance: The compounded milbemycin oxime suspensions evaluated in this study deviated by more than 10% from their labelled strength in five of the six lots. Clinical efficacy of compounded milbemycin oxime suspensions remains unknown and the use of these products should be discouraged at this time.
INTRODUCTION
In the USA, veterinarians are allowed to prescribe compounded medications under the Animal Medicinal Drug Use Clarification Act (AMDUCA), as long as they comply with extra label drug use guidelines set forth by the Food and Drug Administration (FDA) (Boothe 2006) . In 1996, the FDA made available the Compliance Policy Guide (CPG) section 608.400: Compounding of Drugs for Use in Animals, which outlines conditions in which veterinarians are able to prescribe a compounded medication. The interpretation of these regulations state that the legal compounding of drugs for use in animals should not include situations in which there is an approved animal or human drug that will meet the need of the patient (CPG 2003) . In addition, the United States Pharmacopeia (USP) provides standards and requirements for pharmaceutical compounding of non-sterile preparations which include criteria stating that the active pharmaceutical ingredient in a compounded preparation should be within the acceptable range of 90% to 110% of the labelled quantity (Allen et al. 2014 , USP 2016 . To date, oversight bodies do not usually mandate testing of compounded products and many pharmacies do not pursue quality assurance to verify product accuracy and potency for compounded products (Boothe 2006 , Umstead et al. 2012 , USP 2015 . Published data regarding compounded preparations is limited, but growing, with many suggesting these products are inferior to proprietary or generic formulations. Several recent reports have highlighted this issue, which include investigations ttp://www.bsava.com/ evaluating compounded cyclosporine, doxycycline and trilostane (Cook et al. 2012 , Umstead et al. 2012 , Papich et al. 2013 . The concerns raised by these investigations are further magnified when the medication to be compounded has a narrow therapeutic index.
Milbemycin oxime (MO), which consists of the derivatives MO A 4 and MO A 3 in an 80% to 20% ratio, is a commonly used macrocyclic lactone (ML) in veterinary medicine with broad spectrum activity against several nematodes and arthropods (McKellar & Benchaoui 1996) . MLs act via stimulating invertebrate-specific, glutamate-gated chloride channels, resulting in membrane hyperpolarisation, flaccid paralysis and death (McKellar & Benchaoui 1996) . Incidentally, they also activate inhibitory GABA A receptors found in the mammalian central nervous system, which is protected by the blood-brain barrier and the pumping activity of permeability glycoprotein (P-gp) (Jung et al. 2002 , Sieghart 2006 . Patients with a mutation in the ABCB1 gene (ABCB1-1Δ, formerly known as MDR1) are predisposed to severe CNS depression, resulting from defective P-gp in the presence of MLs (Mealey 2008) . Previous investigations with ABCB1 mutant dogs have demonstrated less severe signs of neurologic toxicity with MO when compared to ivermectin (Mealey 2008 , Merola & Eubig 2012 . As a result, despite MO's narrow therapeutic index in P-gp defective dogs, it has been considered a safer therapeutic option for treatment of generalised demodicosis. Production of the veterinary proprietary product solely containing MO (Interceptor®; Elanco) for use in the USA was temporarily ceased in 2011 (VIN 2011) . This led to the use of compounded MO formulations for the treatment of canine generalised demodicosis. Despite the return of Interceptor® to the US veterinary marketplace, compounded formulations of MO are still available through regional and national compounding pharmacies.
The aim of this study was to investigate the accuracy, potency and reproducibility of MO when compounded as an aqueous suspension.
MATERIALS AND METHODS
Pharmacy and product selection An internet search identified compounding pharmacies that advertised services to veterinarians in the USA. A total of 85 pharmacies were identified and contacted anonymously to inquire if compounded MO formulations were produced and, if so, what formulations and strengths existed. Ten pharmacies were actively compounding a MO formulation and from these five were producing an aqueous suspension of similar strength and provided services to our region. From these five pharmacies, two were selected via a random number computer-generated sequence. The primary investigator was blinded to all pharmacy identifications from the onset of the study through interpretation of data. Products were ordered for "in clinic use" from both pharmacies to prevent pharmacist awareness of the intent of product purchase so as to ensure "typical" compounding practices were employed and avoid excessive attention to detail during preparation. Prescriptions were placed at three different times to both pharmacies, with each order referred to as a "lot." Each lot consisted of two bottles of a 20 mg/mL MO aqueous suspension from each pharmacy. Orders were placed at least 7, but no more than 21, days apart. Both bottles from each lot were subjected to one of two different storage conditions: one bottle was stored protected from light at room temperature, while the other bottle was placed in a controlled refrigerated environment (2 to 8 °C).
MO sample preparation, derivitisation and quantification All preparations from each lot were sampled and evaluated at four separate time points from the order date (day 7, 14, 21 and 28). Each lot was quantitated in triplicate at each measurement time point. The 30 mL amber vials received from each pharmacy were vigorously shaken for 20 seconds to ensure a thorough, homogenous mixture of the compounded MO aqueous suspension before extraction. In triplicate, three 100 μL aliquots of compounded MO from each lot were partitioned into three separate 15 mL polypropylene centrifuge tubes (Sigma-Aldrich; St. Louis, MO, USA). Immediately, 1.9 mL of water was added to each tube which was then mixed using a Vortex-Genie® 2 (Thermo Fisher-Scientific; Waltham, MA, USA) for 20 seconds each. Once a homogenous solution was achieved, 8.0 mL of acetonitrile (Thermo Fisher-Scientific) was added to each of the three centrifuge tubes. Following vortex mixing, 0.25 mL of each of the three replications were transferred into three new 15 mL polypropylene centrifuge tubes. This step was followed by the addition of 4.75 mL of acetonitrile to each new preparation for further dilution. After adequate mixing, 100 μL of each final replicate was transferred into a correspondingly labelled 7 mL clear glass vial (Sigma-Aldrich) with a screw-on lid to prevent evaporation.
Each prepared replicate to be run by high-performance liquid chromatography (HPLC) underwent further derivatisation by adding in 175 μL of 1-methylimidazole/acetonitrile (SigmaAldrich) (2:7), 175 μL of trifluoroacetic anhydride/acetonitrile (Thermo Fisher-Scientific) (2:7) and 50 μL of acetic acid (Thermo Fisher-Scientific). The derivatisation process was completed under a laboratory fume hood. Each 7 mL glass vial was capped and gently swirled to mix the newly added contents. The samples were incubated at 65°C in a digital dry heating block (Thermo Fisher-Scientific) for 30 minutes. Following heated incubation, the sample vials were removed and allowed to cool at room temperature for 15 minutes.
The contents of MO were separated chromatographically by HPLC and then quantified using fluorescence detection. The HPLC system was manufactured by Dionex® (Sunnyvale, CA, USA). The chromatographic particle separation was conducted on a Syncronis C 18 , 5 μm, 100 Å, 250 mm × 4 mm packed column (Thermo Fisher-Scientific), using a 1.0 mL/min flow rate with a sample injection volume of 20 μL. The drug was eluted from the column using a mobile phase consisting of HPLC grade methanol (Thermo Fisher-Scientific) and water at a v/v (v = volume) ratio of 92.5/7.5 and operated at 60°C. Detection of A 3 and A 4 isoforms of MO exiting the column were achieved using an RF 2000 fluorescence detector (Dionex®) with excitation and emission wavelengths set at 365 and 475 nm, respectively. Peak area originally interpreted as mV/min was then converted to concentration (mg/mL) for each isoform. The chromatographs were integrated using Chromeleon Chromotography Data System software (Dionex®).
To assess the percentage of recovery, a USP reference standard, [MO (80:17; A 4 :A 3 ); Sigma-Aldrich], was also analysed via HPLC. The purpose of this was to identify standard peaks and column retention times which were used as comparative control standards during the analysis of the compounded MO. The standard calibrator solutions for this assay were prepared at the same time and were subjected to the same method of dilution and derivatisation as the experimental assays. The reference standard calibration curve was linear over concentration with a range of quantification of 0.7 to 160 ng/mL with a coefficient of determination of 0.99. Where applicable, data is presented as mean and 95% confidence interval (CI) of the mean.
Statistical analysis
FDA drug stability guidelines advise that: (1) initial potency be within 10% of labelled potency; and (2) potency is considered adequate over time if drug concentrations remains within 90% of original potency. Based upon these recommended guidelines, a power calculation to detect a difference of 10% of potency indicated 10 total measurements (five measurements per group) would be required. As such, a total of nine [MO] measurements at each temperature and each time point were ultimately performed.
For each pharmacy, the potency of each MO formulation for each lot was calculated for both days 7 and 28 measurements. Potency was considered adequate if between 90% and 110%. In addition, the mean percent reduction in [MO] for formulations was between days 7 and 28 was calculated. The day 7 mean A 4 /A 3 ratios were compared between each pharmacy using an unpaired, two-sided Student's t-test. To evaluate changes in [MO] over the duration of the study, a repeated-measures, two-way analysis of variance (ANOVA) was performed with time and temperature set as explanatory variables and the lot variable controlled by the repeated measures assessment. Similarly, changes in the A 4 / A 3 ratio over the duration of the study were examined with a repeated-measures, two-way ANOVA with time and temperature set as explanatory variables and the lot variable controlled by the repeated measures assessment. Sidak's multiple comparisons were performed to determine if there were differences in the [MO] between refrigerated and room temperature samples. For these two later assessments, separate analyses were performed for milbemycin product from each pharmacy. For all evaluations, significance was set at P < 0.05. Statistical testing was performed with two commercially available software programmes (Graphpad Prism 6. Graphpad Software, Inc. and MedCalc 18. MedCalc Software.)
RESULTS
All products arrived at ambient room temperature, the day after order placement. Pharmacy A samples lacked directions regarding storage temperature or instructions to shake the suspension before use. Pharmacy B formulations arrived with directions to refrigerate and shake before use. Labelled beyond use dates were 1 year and 6 months for Pharmacy A and B, respectively. In addition, the mean MO composition of Pharmacy A determined via HPLC was 93:7 A 4 :A 3 while Pharmacy B repeatedly yielded a mean ratio of 83:17 A 4 :A 3 ; mean A 4 :A 3 of Pharmacy A was different than the mean A 4 :A 3 of Pharmacy B (P < 0.01) The USP reference standard control yielded a ratio of 83:17 A 4 :A 3 .
Using the USP acceptance criteria of ≥90% but ≤110%, five of six lots failed to meet the target potency at day 7 (Table 1) . Of the three lots produced by both pharmacies, only one lot from Pharmacy B fell within the USP acceptable range on the day 7 measurement. The average concentration on day 7 for Pharmacy A samples was 16.29 mg/mL (CI: 15.66 to 16.92) with a CV of Time was identified as a significant explanatory variable for the changes in [MO] (P < 0.01) but temperature and the interaction of time-temperature were not identified as explanatory (P = 0.62 and P = 0.41, respectively). No statistical differences in mean [MO] between the refrigerated and room-temperature samples were observed at any time point. The mean A 4 :A 3 was increased on day 28 relative to day 7 (14.92 versus 13.49, respectively, P = 0.01) but there were no differences between A 4 :A 3 on days 7, 14 and 21 nor between days 14, 21 and 28. For changes in A 4 :A 3 , time, storage temperature, and the interaction between timetemperature were significant explanatory variables (P = 0.02, P = 0.01 and P = 0.02, respectively).
For potency of MO formulations from Pharmacy B, the [MO] on day 7 was higher than the [MO] on days 14, 21 and 28 (P < 0.01 for all comparisons). However, there were no statistical differences in the [MO] between days 14, 21 and 28. Time was also a significant explanatory variable for the change in [MO] (P < 0.01) but temperature and the interaction of time-temperature were not identified as explanatory (P = 0.63 and P = 0.78, respectively). No statistical differences in mean [MO] between the refrigerated and room-temperature samples were observed at any time point. The mean A 4 :A 3 were not statistically different between days 7, 14, 21 and 28; time, storage temperature, and the interaction between time-temperature were not significant explanatory variables (P = 0.24, P = 0.06 and P = 0.17, respectively).
DISCUSSION
The findings of this investigation add to the growing concern surrounding compounded preparations in veterinary medicine and suggest that an air of scepticism is appropriate when recommending them for therapeutic use. This is especially true when commercially produced products are available, even if their use is off-label. Our study revealed that of the initial day 7 samples, only one of six compounded formulations were within the USPdefined acceptable range of 90% to 110% of labelled strength. The day 7 values were alarming, given the narrow therapeutic index for MO in demodex treatment protocols with five of six samples deviating by more than 10% from their labelled strength (day 7 concentrations ranged from 72% to 130% of the labelled content). Previous investigations have shown dogs carrying the ABCB1-1Δ mutation developed neurologic adverse events after being administered daily dosages of 1.6 mg/kg of MO (Barbet et al. 2009 ). This is specifically concerning considering Pharmacy B: Lot 2 revealed a day 7 concentration of 26.07 mg/mL (CI: 24.98 to 27.16). Assuming there is adequate systemic absorption, the use of this suspension could lead to overdosage and severe neurologic adverse events in predisposed dogs.
A 20 mg/mL aqueous suspension was chosen for evaluation as it was the most commonly prepared formulation based on pharmacy survey and represented prescribing trends by veterinarians. Low and high concentration variations from the commonly prepared preparations were avoided as an increased likelihood for introduction of variance and error was expected. It is important to note that at the initial time of this investigation the isoxazoline derivatives were not widely available and alternative, effective therapeutic options were limited in dogs with heterozygote or homozygote P-gp mutations. It is for this reason that the use of these products rose with the absence of Interceptor® from the market place. The impetus for this particular study was due to concern over maintained potency of MO and larger quantities being ordered due to protracted treatment courses in dogs with generalised demodicosis.
It is interesting to note that samples from Pharmacy A appeared inaccurately prepared, as highlighted by the mean day 7 starting concentration of 16.3 mg/mL (CI: 15.66 to 16.92) but there was fair reproducibility (CV = 11%). The opposite was true for Pharmacy B, with samples at day 7 having a mean concentration of 20.46 mg/mL (CI: 19.83 to 21.08) but the low reproducibility (CV = 22%) illustrating unacceptable variation from lot to lot. It should be noted that neither preparation protocols or MO drug sources were requested from either pharmacy, so direct comparisons of the processes utilised in their formulations could not be reviewed.
Two other critical points of interest with regards to the findings of this investigation surround the beyond-use date labelling differences between the pharmacies and the starting chemical compositions of their products. First, the assigned beyond-use dates were 12 and 6 months for Pharmacy A and B, respectively. A significant reduction in mean potency for both pharmacies was observed when the day 7 measured concentrations were compared to all other observed time points. This was most pronounced by day 28 for both pharmacies with a mean decrease of 3.64 mg/mL for Pharmacy A and 3.62 mg/mL for Pharmacy B in measured potencies. These observations call into question adherence to limitations on beyond-use labelling by these pharmacies (USP 2015). While we do advise that compounded formulations be administered before their assigned beyond-use date, it should be noted that the potency of a preparation is not assured at any time point in the absence of scientific stability data. Secondly, the MO substrate used by Pharmacy A was composed of a ratio of 93:7 A 4 :A 3 while Pharmacy B was 83:17 A 4 :A 3 . Both vary from the proprietary drug exclusively containing MO, which has a listed derivative composition of 80:20 A 4 :A 3 (Elanco Animal Health 2016). Although Pharmacy B was similar to the proprietary product, it does not mean an FDA-approved finished form of the drug was used in the preparation of the formulation. This again questions both pharmacies adherence to federal guidelines related to the source for any compounded medication (CPG 2003) . However, it should be noted that regardless of the MO isoform composition used to prepare their compounded formulations, all lots produced by each pharmacy displayed a relatively consistent decrease in potency over the 28 day span.
It is also important to note the major limitations of this study. First, the findings of this investigation cannot be extrapolated to all compounded drug formulations or compounding pharmacies, as only a single formulation from two pharmacies was evaluated. Secondly, this study only evaluated the potency, reproducibility and maintenance of potency of these MO compounded formulations. No information concerning the bioavailability of therapeutic efficacy of these products was evaluated. However, we feel it is important to note that differences in bioavailability have been observed in patients administered compounded and proprietary preparations (Mawby et al. 2014) . As a result, follow-up studies would be required to assess the bioavailability and therapeutic efficacy of compounded MO. Based upon our results and the unknown pharmacokinetics and pharmacodynamics of compounded MO formulations, we believe that compounded MO products should not be used clinically.
In conclusion, the majority of compounded aqueous MO formulations evaluated in this investigation exhibited neither accurate, reproducible or maintained potency as defined by the USP guidelines. The inconsistencies and lack of compliance by the compounding pharmacies observed in this study adds to the growing evidence that caution should be used when prescribing compounded preparations. In light of the results of this study and the return of a proprietary MO only product to the veterinary marketplace, the use of compounded MO should be discouraged at this time.
